Biocon Biologics Ltd (BBL), the Biosimilar and Subsidiary Company of Biocon Ltd, has announced a licenseeon license to market Yesafili, a medication used to treat histalmological conditions. The agreement allows the company to launch the product in the US. In the second half of 2026 or before, under certain circumstances.
The companies executed the conciliation agreement to dismiss the pending appeal in the United States Court of Appeals for the Federal Circuit (USCAFC) and the Pending Litigation Court for the Northern District of Virginia Western, Clarksburg Dision.
YESAFILI is used to treat several ophthalmology conditions, such as neovascular macular degeneration (humid AMD) related to age, visual deterioration due to macular edema secondary to the occlusion of the retinal, visual vein) and choroidal neovascularization of the diabetal macopma (CNV myopia). It is a biosimilar to its Eylea reference product (AFLIBER concept).
For the focus of its commercial use, an integral package of analytical, non -clinical and clinical data was made that Yesafili has similarities in quality, safety and effectiveness for the eyes.
“This settlement clears the path for biocon biologics to be among the first to bring a reliable, High-Qualy Afgicept Biosimilar to Patients and Healthcare providers in the us. Strategic entry into ophthalmology, Expanding Our Footprint in the US and Advancing Our Mission to increase access to treatments that change their lives, ”said Shreehas also, CEO and managing director of Biocon Biologics Ltd.
Last year, the company also signed a task of settlement with Janssen to market BMAB 1200, a biosimilar or stellar, used for the treatment of psoriasis, crohn disease, ulcerative colitis, plaque psoriasis and psoriatic arthis.
The company has brought nine biosimilar of its pipe or 20 products to the main markets such as the United States, Europe, Australia, Canada and Japan. Earlier this month, the company received the approval of Jobevne, a medicine for the treatment of cancer that became the fourth biosimilar of the company’s oncology in the United States. The shares of the company quoted ₹ 328.95, an axis of 3.92 percent or 15:03 pm on April 15.
(With BL inputs informing Nethra Sailesh internal)
Posted on April 15, 2025
